Niagen Bioscience Director Receives 20,000 Stock Options at $14.13 Strike Price

Form 4 filing reveals that Wendy Wing Tak Yu, Director at Niagen Bioscience (NAGE), received a stock option grant on June 24, 2025.

Rhea-AI Filing Summary

Form 4 filing reveals that Wendy Wing Tak Yu, Director at Niagen Bioscience (NAGE), received a stock option grant on June 24, 2025. The derivative securities transaction details include:

• Granted 20,000 stock options to purchase common stock
• Exercise price set at $14.13 per share
• 100% vesting scheduled for June 24, 2026
• Options expire on June 23, 2035

The filing, submitted by attorney-in-fact Jeong James Lee on June 26, 2025, indicates a standard director compensation grant with a one-year cliff vesting schedule. This represents a new position in derivative securities for the director, with direct ownership of all 20,000 options.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider YU Wing Tak Wendy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. Option vests 100% on June 24, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did NAGE director Yu Wing Tak Wendy receive on June 24, 2025?

According to the Form 4 filing, NAGE director Yu Wing Tak Wendy received 20,000 stock options with an exercise price of $14.13 per share on June 24, 2025.

What is the vesting schedule for Yu Wing Tak Wendy's NAGE stock options granted in June 2025?

The stock options granted to Yu Wing Tak Wendy vest 100% on June 24, 2026, which is a one-year cliff vesting schedule.

When do NAGE director Yu Wing Tak Wendy's stock options expire?

The stock options granted to Yu Wing Tak Wendy expire on June 23, 2035, giving them a 10-year term from the grant date.

What is the exercise price of NAGE stock options granted to director Yu Wing Tak Wendy in June 2025?

The exercise price (conversion price) of the stock options granted to Yu Wing Tak Wendy is $14.13 per share.

Did NAGE director Yu Wing Tak Wendy make any direct stock purchases or sales in this Form 4 filing?

No, the Form 4 filing shows no direct purchases or sales of NAGE common stock. The only reported transaction was the grant of stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 05:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YU Wing Tak Wendy

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.13	06/24/2025		A		20,000		06/24/2026(1)	06/23/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Option vests 100% on June 24, 2026.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.